IRIS UniCatt

De Luca, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.365
EU - Europa 6.898
AS - Asia 3.065
SA - Sud America 599
AF - Africa 59
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 7
Totale 18.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.260
DE - Germania 1.849
CN - Cina 1.307
SE - Svezia 1.080
SG - Singapore 1.036
UA - Ucraina 895
FR - Francia 685
PL - Polonia 671
BR - Brasile 557
IT - Italia 516
IE - Irlanda 383
ID - Indonesia 240
GB - Regno Unito 232
FI - Finlandia 226
IN - India 173
RU - Federazione Russa 162
TR - Turchia 88
CA - Canada 61
HK - Hong Kong 46
BE - Belgio 37
NL - Olanda 36
AT - Austria 32
JP - Giappone 28
IR - Iran 23
VN - Vietnam 22
MX - Messico 19
ES - Italia 13
KR - Corea 13
AR - Argentina 12
ZA - Sudafrica 12
BZ - Belize 11
PK - Pakistan 10
CH - Svizzera 9
LT - Lituania 9
MA - Marocco 9
BD - Bangladesh 8
CM - Camerun 8
IQ - Iraq 8
AE - Emirati Arabi Uniti 7
BG - Bulgaria 7
CI - Costa d'Avorio 7
EC - Ecuador 7
EU - Europa 7
PH - Filippine 7
AZ - Azerbaigian 6
GR - Grecia 6
RO - Romania 6
CO - Colombia 5
CZ - Repubblica Ceca 5
DK - Danimarca 5
EG - Egitto 5
PE - Perù 5
PY - Paraguay 5
UZ - Uzbekistan 5
DZ - Algeria 4
EE - Estonia 4
HU - Ungheria 4
IL - Israele 4
KE - Kenya 4
LU - Lussemburgo 4
NZ - Nuova Zelanda 4
VE - Venezuela 4
AU - Australia 3
BY - Bielorussia 3
CL - Cile 3
GE - Georgia 3
JM - Giamaica 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
NI - Nicaragua 3
OM - Oman 3
TN - Tunisia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BN - Brunei Darussalam 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
IM - Isola di Man 2
JO - Giordania 2
KZ - Kazakistan 2
LV - Lettonia 2
PA - Panama 2
PT - Portogallo 2
RS - Serbia 2
TZ - Tanzania 2
UG - Uganda 2
AD - Andorra 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
IS - Islanda 1
MD - Moldavia 1
MK - Macedonia 1
Totale 17.990
Salva come PNG Salva come JPEG
Città #
Chandler 1.369
Jacksonville 569
Singapore 528
Kraków 520
Ashburn 473
San Mateo 406
Dublin 380
New York 304
Dearborn 287
Nanjing 275
Jakarta 238
Wilmington 229
Ann Arbor 171
Houston 168
Beijing 163
Lawrence 161
Cattolica 151
Warsaw 146
Boston 144
Redmond 143
Hangzhou 137
Woodbridge 132
Nürnberg 106
Moscow 105
Seattle 104
Nanchang 102
Milan 91
Redwood City 91
Izmir 79
Princeton 75
Lancaster 73
Boardman 70
Mountain View 67
University Park 64
Shenyang 58
Fairfield 54
Los Angeles 50
Kunming 48
Guangzhou 46
Bremen 43
Hebei 43
Norwalk 43
Changsha 40
Hong Kong 40
São Paulo 39
Rome 37
Brussels 36
Munich 35
Fremont 34
Jiaxing 34
Marseille 34
Frankfurt am Main 30
Ottawa 30
Falls Church 28
Jinan 28
Philadelphia 28
Tianjin 28
Hefei 27
San Jose 27
Shanghai 27
Pune 26
Cambridge 25
Rio de Janeiro 24
Verona 24
Düsseldorf 22
The Dalles 22
Zhengzhou 22
Chicago 21
Helsinki 21
Leawood 21
London 21
Scottsdale 19
Simi Valley 19
Belo Horizonte 17
Nuremberg 17
Washington 17
Paris 16
Lauterbourg 15
Vienna 15
Amsterdam 14
Indiana 14
Toronto 14
Augusta 13
Detroit 12
Edinburgh 12
Fuzhou 12
Belize City 11
Las Vegas 11
Curitiba 10
Hanoi 10
San Francisco 10
Brasília 9
Buffalo 9
Andover 8
Changchun 8
Porto Alegre 8
Portsmouth 8
Santa Clara 8
Tokyo 8
Wenzhou 8
Totale 9.689
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 331
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 269
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 235
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 221
Common genetic variation and the control of HIV-1 in humans. 217
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 189
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 189
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 171
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 167
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 149
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 147
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 146
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 144
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 141
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 134
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 131
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 131
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 131
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 129
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 123
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 120
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 120
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 119
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 118
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 118
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 117
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 117
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 117
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 116
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 114
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 113
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 112
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 112
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 110
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 108
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 108
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 107
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 107
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 107
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 106
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 106
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study 105
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 104
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 104
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 103
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 103
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 102
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 102
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 102
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 101
Phemphigus vulgaris in a human-immunodeficiency-virus-infected patient. 100
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 99
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 99
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 98
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 98
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 97
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 96
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 95
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 95
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 94
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 94
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 94
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). 93
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 92
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 92
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 92
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 91
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 91
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 90
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 88
Lipid-lowering effect of tenofovir in HIV-infected patients 88
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 88
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 88
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 88
Long term follow-up of Nevirapine-treated patients in a single centre cohort 87
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 87
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 87
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 86
Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 86
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 86
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 86
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. 85
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 84
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 84
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases 83
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 83
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 82
A novel methodology for large-scale phylogeny partition 82
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 82
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients 81
Stochastic Modelling of Genotypic Drug-Resistance for Human Immunodeficiency Virus towards Long-Term Combination Therapy Optimisation 81
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study 81
An outbreak of HIV-1 subtype G among Italian injecting drug users 81
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 80
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 80
Italian consensus statement on management of HIV-infected individualswith advanced disease naive to antiretroviral therapy 80
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 80
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 80
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 80
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 80
Totale 11.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.089
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020417 0 0 0 0 0 0 0 0 0 0 188 229
2020/20211.750 134 207 45 199 215 99 191 31 272 38 280 39
2021/20221.870 185 198 43 94 68 81 31 315 70 137 260 388
2022/20233.527 475 477 286 502 307 453 82 297 448 36 106 58
2023/20241.724 73 554 31 136 51 379 79 34 18 28 190 151
2024/20252.651 83 101 269 76 277 131 101 207 568 269 569 0
Totale 18.191